Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
EPCR-PAR1 biased signaling regulates perfusion recovery and neovascularization in peripheral ischemia
Magdalena L. Bochenek, Rajinikanth Gogiraju, Stefanie Großmann, Janina Krug, Jennifer Orth, Sabine Reyda, George S. Georgiadis, Henri M. Spronk, Stavros Konstantinides, Thomas Münzel, John H. Griffin, Philipp Wild, Christine Espinola-Klein, Wolfram Ruf, Katrin Schäfer
Magdalena L. Bochenek, Rajinikanth Gogiraju, Stefanie Großmann, Janina Krug, Jennifer Orth, Sabine Reyda, George S. Georgiadis, Henri M. Spronk, Stavros Konstantinides, Thomas Münzel, John H. Griffin, Philipp Wild, Christine Espinola-Klein, Wolfram Ruf, Katrin Schäfer
View: Text | PDF
Research Article Angiogenesis Vascular biology

EPCR-PAR1 biased signaling regulates perfusion recovery and neovascularization in peripheral ischemia

  • Text
  • PDF
Abstract

Blood clot formation initiates ischemic events, but coagulation roles during postischemic tissue repair are poorly understood. The endothelial protein C receptor (EPCR) regulates coagulation, as well as immune and vascular signaling, by protease activated receptors (PARs). Here, we show that endothelial EPCR-PAR1 signaling supports reperfusion and neovascularization in hindlimb ischemia in mice. Whereas deletion of PAR2 or PAR4 did not impair angiogenesis, EPCR and PAR1 deficiency or PAR1 resistance to cleavage by activated protein C caused markedly reduced postischemic reperfusion in vivo and angiogenesis in vitro. These findings were corroborated by biased PAR1 agonism in isolated primary endothelial cells. Loss of EPCR-PAR1 signaling upregulated hemoglobin expression and reduced endothelial nitric oxide (NO) bioavailability. Defective angiogenic sprouting was rescued by the NO donor DETA-NO, whereas NO scavenging increased hemoglobin and mesenchymal marker expression in human and mouse endothelial cells. Vascular specimens from patients with ischemic peripheral artery disease exhibited increased hemoglobin expression, and soluble EPCR and NO levels were reduced in plasma. Our data implicate endothelial EPCR-PAR1 signaling in the hypoxic response of endothelial cells and identify suppression of hemoglobin expression as an unexpected link between coagulation signaling, preservation of endothelial cell NO bioavailability, support of neovascularization, and prevention of fibrosis.

Authors

Magdalena L. Bochenek, Rajinikanth Gogiraju, Stefanie Großmann, Janina Krug, Jennifer Orth, Sabine Reyda, George S. Georgiadis, Henri M. Spronk, Stavros Konstantinides, Thomas Münzel, John H. Griffin, Philipp Wild, Christine Espinola-Klein, Wolfram Ruf, Katrin Schäfer

×

Figure 8

Mesenchymal marker expression in endothelial cells and hindlimbs in the presence of altered NO signaling.

Options: View larger image (or click on image) Download as PowerPoint
Mesenchymal marker expression in endothelial cells and hindlimbs in the ...
(A–C) Human microvascular endothelial cells were treated with PTIO (100 μM), ODQ (50 μM), or the NO donor DETA-NO (100 μM), and changes in the mRNA transcript levels of platelet-endothelial cell adhesion molecule (PECAM1) (A), smooth muscle α-actin (ACTA2) (B), and platelet-derived growth factor receptor-β (PDGFRB) (C) were examined 4 days later using qPCR; n = 3-4 biological replicates. One-way ANOVA, Sidak’s multiple-comparison test. *P < 0.05 and ***P < 0.001 versus control; ##P < 0.01 and ###P < 0.001 versus ODQ-treated cells. (D, E, H, and J) Representative confocal images and quantitative analysis after immunostaining of SMA (red) and CD31 expression (green) in ischemic (D and H) and nonischemic hindlimb muscles of EPCRfl/fl Tie2.Cre mice and EPCRfl/fl littermate control mice or C57BL/6N, C57BL/6N PAR1 R41Q, and C57BL/6N PAR1 R46Q mutant mice (E and J); n = 5 biological replicates. DAPI+ cell nuclei appear blue. Scale bars: 10 μm. (F, G, I, and K) Representative confocal images and (I) quantitative analysis after immunostaining of PDGFRB (red) and CD31 expression (green) in ischemic and nonischemic hindlimb muscles of EPCRfl/fl Tie2.Cre and EPCRfl/fl control littermate mice (F and I) or C57BL/6N, C57BL/6N PAR1 R41Q, and C57BL/6N PAR1 R46Q mutant mice at day 28 after ischemia (G and K); n = 5 biological replicates. DAPI+ cell nuclei appear blue. Scale bars: 10 μm. *P < 0.05 and **P < 0.01 versus nonischemic, contralateral hindlimb; ##P < 0.01, ###P < 0.001, and ####P < 0.0001 versus C57BL/6N control mice; §§P < 0.01 versus C57BL/6N PAR1 R41Q mice. Two-way ANOVA, Sidak’s multiple-comparison test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts